絞り込み

16545

広告

辺野古承認撤回 県が審査請求弁明書を国交相に送付 (毎日新聞)

[PR] 沖縄県は19日、米軍普天間飛行場(宜野湾市)の名護市辺野古移設を巡り、辺野古沿岸部の埋め立て承認を撤回した県への対抗措置として、政府が行った行政不服審...

  1. 免疫受容体CD300fの機能促進で偽アレ...
  2. 伊勢谷友介と森星のデートをNEWSポスト...
  3. 韓中首脳「朝鮮半島問題、解決の機が熟しつ...
  4. 2025年万博 今週開催地が決定 大阪府...

ニュース一覧

Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance.

著者 Imberti D , Cimminiello C , di Nisio M , Marietta M , Polo Friz H , Ageno W
Expert Opin Pharmacother.2018 Jul 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (50view , 0users)

Full Text Sources

Miscellaneous

Most of the current clinical guidelines recommend the use of Low Molecular Weight Heparins (LMWHs) for cancer-associated thrombosis (CAT). The Hokusai VTE-cancer trial reported the first results of a direct comparison between a direct oral anticoagulant (DOAC), edoxaban, and LMWH in this setting. Areas covered: This review aims to critically appraise the currently available evidence on the efficacy and safety of anticoagulant agents for the long-term treatment of CAT and to provide an expert opinion and guidance in this field. Expert opinion: Based on the available evidence, DOACs represent a valid alternative to LMWH for the treatment of CAT for the majority of patients with active cancer. Currently, most solid evidence comes from the HOKUSAI-VTE cancer study, which showed that edoxaban is non-inferior to the LMWH dalteparin, with a trend toward fewer recurrent venous thromboembolic events, but with more major bleeding events. Similar findings were reported with rivaroxaban, although the study was not sufficiently powered to allow definitive conclusions. The majority of bleeding events occurred in the upper gastrointestinal tract and in patients with gastrointestinal cancer. Thus, LMWH remains the preferred option for patients with gastrointestinal cancer. Additional studies aimed to confirm these findings with other DOACs are now warranted.
PMID: 29963962 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード